VIP: When a Mechanism Meets a Clinical Test
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Vasoactive intestinal peptide, or VIP, has attracted interest for its biological effects in the lungs. Aviptadil is the synthetic VIP studied in clinical research. The TESICO randomized trial tested intravenous aviptadil in people hospitalized with severe COVID-19 respiratory failure. Its primary outcome assessed recovery status through day 90. Aviptadil did not significantly improve that outcome compared with placebo. The trial was stopped for futility. Low blood pressure, flushing, and diarrhea were important safety observations. This result applies to the tested illness, route, and setting. It illustrates why laboratory mechanisms need clinical testing, without settling every research question about VIP.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] TESICO investigators (2023): Intravenous aviptadil and remdesivir for COVID-19-associated hypoxaemic respiratory failure, TESICO
https://pubmed.ncbi.nlm.nih.gov/37348524/
Primary human randomized phase 3 trial

[2] TESICO investigators (2023): Full trial report
https://pmc.ncbi.nlm.nih.gov/articles/PMC10527239/
Primary human randomized trial full text

EVIDENCE LIMITATIONS
The negative result concerns severe COVID-19 respiratory failure and intravenous aviptadil.
It does not prove all VIP-related molecules or routes ineffective in every disease.
Do not transfer laboratory lung effects into a treatment claim.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
VIP: When a Mechanism Meets a Clinical Test